Current and future management of recurrent respiratory papillomatosis
Autor: | Brad W. deSilva, Ryan Ivancic, Hassan Iqbal, Quintin Pan, Laura Matrka |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
education.field_of_study business.industry Transmission (medicine) medicine.medical_treatment Incidence (epidemiology) Population General Medicine HPV vaccines Evidence-based medicine medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis medicine Recurrent Respiratory Papillomatosis 030223 otorhinolaryngology Intensive care medicine business education Adjuvant Laryngeal papillomatosis |
Zdroj: | Laryngoscope Investigative Otolaryngology. 3:22-34 |
ISSN: | 2378-8038 |
DOI: | 10.1002/lio2.132 |
Popis: | Objectives Recurrent respiratory papillomatosis (RRP) is a chronic disease of the respiratory tract that occurs in both children and adults. It is caused by the human papillomavirus (HPV), in particular low-risk HPV6 and HPV11, and aggressiveness varies among patients. RRP remains a chronic disease that is difficult to manage. This review provides perspectives on current and future management of RRP. Results The current standard of care is surgical excision, with adjuvant therapies as needed. Surgical management of RRP has evolved with the introduction of microdebriders and photoangiolytic lasers; the latter can now be used in the office setting. Numerous adjuvant pharmacologic therapies have been utilized with some success. Also, exciting preliminary data show that HPV vaccines may prolong the time to recurrence in the RRP population. There is also optimism that wide-spread HPV vaccination could reduce RRP incidence indirectly by preventing vertical HPV transmission to newborns. Conclusion To date, the biology of RRP is not well understood, although it has been noted to become more aggressive in the setting of immune suppression. Additional research is needed to better understand immune system dysfunction in RRP such that immunomodulatory approaches may be developed for RRP management. Level of evidence 4. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |